Patrick D. Yeramian - Mar 16, 2023 Form 4/A - Amendment Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol
AMLX
Transactions as of
Mar 16, 2023
Transactions value $
-$1,613,939
Form type
4/A - Amendment
Date filed
3/24/2023, 06:45 PM
Date Of Original Report
Mar 20, 2023
Previous filing
Jan 10, 2023
Next filing
Apr 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Options Exercise $920 +2.79K +1.37% $0.33* 207K Mar 16, 2023 Direct F1, F2
transaction AMLX Common Stock Options Exercise $11.1K +30K +14.51% $0.37* 237K Mar 16, 2023 Direct F1, F2
transaction AMLX Common Stock Options Exercise $115K +16.7K +7.06% $6.88 254K Mar 16, 2023 Direct F1, F2
transaction AMLX Common Stock Sale -$1.66M -52.2K -20.57% $31.85 202K Mar 16, 2023 Direct F1, F2, F3
transaction AMLX Common Stock Sale -$78.4K -2.42K -1.2% $32.43 199K Mar 16, 2023 Direct F1, F2, F4
transaction AMLX Common Stock Award $0 +9.17K +4.6% $0.00 208K Mar 16, 2023 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (right to buy) Award $0 +41.3K $0.00 41.3K Mar 16, 2023 Common Stock 41.3K $32.08 Direct F6
transaction AMLX Stock Option (right to buy) Options Exercise $0 -2.79K -100% $0.00* 0 Mar 16, 2023 Common Stock 2.79K $0.33 Direct F1, F2, F7
transaction AMLX Stock Option (right to buy) Options Exercise $0 -30K -32.47% $0.00 62.5K Mar 16, 2023 Common Stock 30K $0.37 Direct F1, F2, F8
transaction AMLX Stock Option (right to buy) Options Exercise $0 -16.7K -25.77% $0.00 48.3K Mar 16, 2023 Common Stock 16.7K $6.88 Direct F1, F2, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.
F2 These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
F6 1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
F7 The shares subject to such option are vested and currently exercisable.
F8 As of the date of this filing, 39,688 shares subject to the option are vested and exercisable. 52,819 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.
F9 16,256 shares underlying this option vested on February 19, 2022, with the remaining shares vesting in monthly installments of 1,354 shares thereafter.

Remarks:

Exhibit List: Exhibit 24. This Power of Attorney was inadvertently omitted from the Form 3 filed on January 6, 2022.